NF-κ B and Androgen Receptor Variant 7 Induce Expression of SRD 5 A Isoforms and Confer 5 ARI Resistance
暂无分享,去创建一个
R. Matusik | O. Franco | S. Hayward | N. Miller | D. Strand | P. Clark | J. Jin | David C. Austin | O. Hameed | Douglas W. Strand | Harold L. Love | M. Magdalena | Grabowska | Ren
[1] R. Matusik,et al. NF‐κB and androgen receptor variant expression correlate with human BPH progression , 2016, The Prostate.
[2] R. Matusik,et al. Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia. , 2016, Endocrinology.
[3] W. Isaacs,et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.
[4] R. Matusik,et al. Inhibition of NF-kappa B signaling restores responsiveness of castrate resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor variants expression , 2014, Oncogene.
[5] J. Mohler,et al. Androgenic biomarker profiling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry , 2014 .
[6] S. Hayward,et al. Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP‐1 transcription factor network , 2014, The Prostate.
[7] C. Evans,et al. MP24-07 NF-KAPPAB2/P52 INDUCES RESISTANCE TO ENZALUTAMIDE IN PROSTATE CANCER: ROLE OF ANDROGEN RECEPTOR AND ITS VARIANTS , 2014 .
[8] L. Vignozzi,et al. Benign Prostatic Hyperplasia: A New Metabolic Disease of the Aging Male and Its Correlation with Sexual Dysfunctions , 2014, International journal of endocrinology.
[9] Zhiyong Guo,et al. Androgen Receptor Splice Variant AR3 Promotes Prostate Cancer via Modulating Expression of Autocrine/Paracrine Factors* , 2013, The Journal of Biological Chemistry.
[10] W. Willett,et al. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. , 2012, The Journal of urology.
[11] H. Lepor,et al. &agr;-Blockers for benign prostatic hyperplasia: the new era , 2012, Current opinion in urology.
[12] C. Guillemette,et al. SRD5A polymorphisms and biochemical failure after radical prostatectomy. , 2011, European urology.
[13] P. Nelson,et al. Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases , 2011, PloS one.
[14] O. Franco,et al. PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia. , 2011, Differentiation; research in biological diversity.
[15] W. Isaacs,et al. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities , 2011, The Prostate.
[16] W. Bushman,et al. Role of interleukins, IGF and stem cells in BPH. , 2011, Differentiation; research in biological diversity.
[17] D. Tindall,et al. Targeting 5α-reductase for prostate cancer prevention and treatment , 2011, Nature Reviews Urology.
[18] Ming Jiang,et al. Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. , 2011, Cancer research.
[19] N. Socci,et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor , 2010, Proceedings of the National Academy of Sciences.
[20] M. Salto‐Tellez,et al. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer. , 2010, Endocrine-related cancer.
[21] P. Nelson,et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. , 2010, The Journal of clinical investigation.
[22] F. Labrie,et al. Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride , 2010, Hormone molecular biology and clinical investigation.
[23] D. Russell,et al. SRD5A3: A Surprising Role in Glycosylation , 2010, Cell.
[24] H. Freeze,et al. SRD5A3 Is Required for Converting Polyprenol to Dolichol and Is Mutated in a Congenital Glycosylation Disorder , 2010, Cell.
[25] K. McVary,et al. Lower urinary tract symptoms, obesity and the metabolic syndrome , 2010, Current opinion in urology.
[26] S. Hayward,et al. Functional Remodeling of Benign Human Prostatic Tissues In Vivo by Spontaneously Immortalized Progenitor and Intermediate Cells , 2009, Stem cells.
[27] L. Adorini,et al. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. , 2009, International journal of andrology.
[28] Zhiyong Guo,et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.
[29] D. Bostwick,et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. , 2008, European urology.
[30] Matthew S. Hayden,et al. New regulators of NF-κB in inflammation , 2008, Nature Reviews Immunology.
[31] Mitch Dowsett,et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] D. Tindall,et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.
[33] R. Shah,et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.
[34] L. Ferrucci,et al. Metabolic factors associated with benign prostatic hyperplasia. , 2006, The Journal of clinical endocrinology and metabolism.
[35] I Judson,et al. Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer , 2004, British Journal of Cancer.
[36] N. Greenberg,et al. Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype , 2004, Journal of cellular biochemistry.
[37] C. Roehrborn,et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. , 2003, The New England journal of medicine.
[38] G. Cunha,et al. Mouse urogenital development: a practical approach. , 2003, Differentiation; research in biological diversity.
[39] P. Boyle,et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. , 2002, Urology.
[40] P. Leedman,et al. Printed in U.S.A. Copyright © 1999 by The Endocrine Society Differential Posttranscriptional Regulation of Androgen Receptor Gene Expression by Androgen in Prostate and Breast Cancer Cells* , 2022 .
[41] S. Hayward,et al. The rat prostatic epithelial cell line NRP‐152 can differentiate in vivo in response to its stromal environment , 1999, The Prostate.
[42] H. Yamanaka,et al. Androgen-stimulated human prostate epithelial growth mediated by stromal-derived fibroblast growth factor-10. , 1999, Endocrine journal.
[43] R. Dahiya,et al. Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model. , 1998, Differentiation; research in biological diversity.
[44] C. Roehrborn,et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. , 1998, The New England journal of medicine.
[45] D. Mellström,et al. Components of the metabolic syndrome—risk factors for the development of benign prostatic hyperplasia , 1998, Prostate Cancer and Prostatic Diseases.
[46] S. Hayward,et al. Stromal-epithelial interactions in the normal and neoplastic prostate. , 1997, British journal of urology.
[47] Heiko,et al. Transcriptional and posttranscriptional regulation of human androgen receptor expression by androgen. , 1993, Molecular endocrinology.
[48] M. Barry,et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.
[49] F. Habib,et al. Estrogen and androgen signaling in the pathogenesis of BPH , 2011, Nature Reviews Urology.
[50] R. Vessella,et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.
[51] Yusuke Nakamura,et al. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. , 2008, Cancer science.
[52] H. Koyuncu,et al. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. , 2007, European urology.
[53] A. Baldwin,et al. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. , 2006, Oncogene.
[54] J. Rubin,et al. Keratinocyte growth factor: an androgen-regulated mediator of stromal-epithelial interactions in the prostate , 2004, World Journal of Urology.
[55] S. Hayward,et al. The prostate: development and physiology. , 2000, Radiologic clinics of North America.
[56] P. Bollina,et al. A novel coculture model for benign prostatic hyperplasia expressing both isoforms of 5 alpha-reductase. , 1998, The Journal of clinical endocrinology and metabolism.
[57] M. Barry,et al. Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). , 1994, Urology.
[58] J. McNeal. Anatomy of the prostate and morphogenesis of BPH. , 1984, Progress in clinical and biological research.